Table 4.
Subgroup analysis for the prediction of CIN by brain natriuretic peptide.
| Subgroup | Number of studies | Sen (95% CI) | Spe (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) |
|---|---|---|---|---|---|---|
| All studies | 12 | 0.73 (0.67–0.78) | 0.77 (0.71–0.82) | 3.2 (2.5–4.1) | 0.35 (0.29–0.43) | 9 (6–13) |
| Prospective | 9 | 0.75 (0.70–0.80) | 0.73 (0.68–0.78) | 2.8 (2.2–3.5) | 0.34 (0.26–0.44) | 8 (5–14) |
| Average age < 70 years | 10 | 0.74 (0.67–0.79) | 0.78 (0.71–0.83) | 3.3 (2.6–4.3) | 0.34 (0.27–0.42) | 10 (7–14) |
| Country | ||||||
| China | 6 | 0.72 (0.64–0.79) | 0.79 (0.72–0.86) | 3.4 (2.4–4.8) | 0.36 (0.29–0.45) | 9 (6–15) |
| Other countries | 6 | 0.74 (0.67–0.81) | 0.75 (0.67–0.83) | 3.0 (2.2–4.2) | 0.34 (0.23–0.49) | 9 (5–17) |
| Population | ||||||
| AMI | 7 | 0.73 (0.66–0.80) | 0.78 (0.71–0.85) | 3.3 (2.4–4.7) | 0.34 (0.25–0.46) | 10 (5–17) |
| Other population | 5 | 0.73 (0.64–0.81) | 0.76 (0.68–0.85) | 3.0 (2.2–4.1) | 0.37 (0.29–0.47) | 8 (5–12) |
| Index test | ||||||
| NT-proBNP | 8 | 0.75 (0.69–0.81) | 0.76 (0.69–0.83) | 3.1 (2.5–3.9) | 0.33 (0.27–0.41) | 9 (7–13) |
| BNP | 4 | 0.69 (0.60–0.77) | 0.80 (0.71–0.88) | 3.4 (2.0–6.1) | 0.39 (0.27–0.54) | 9 (4–20) |
AMI = acute myocardial infarction, BNP = b-type natriuretic peptide, CI = credible interval, DOR = diagnostic odds ratio, NLR = negative likelihood ratio, NT-proBNP = N-terminal pro-B-type natriuretic peptide, PLR = positive likelihood ratio, SEN = sensitivity, SPE = specificity.